INTRODUCTION The use and availability of oral and inhalable products containing cannabidiol (CBD) as the principal constituent has increased with expanded cannabis/hemp legalization. However, few controlled clinical laboratory studies have evaluated the pharmacodynamic effects of oral or vaporized CBD or CBD-dominant cannabis. METHODS Eighteen healthy adults (9 men; 9 women) completed four, double-blind, double-dummy, drug administration sessions. Sessions were separated by ≥1 week and included self-administration of 100 mg oral CBD, 100 mg vaporized CBD, vaporized CBD-dominant cannabis (100 mg CBD; 3.7 mg THC), and placebo. Study outcomes included: subjective drug effects, vital signs, cognitive/psychomotor performance, and whole blood THC and CBD concentrations. RESULTS Vaporized CBD and CBD-dominant cannabis increased ratings on several subjective items (e.g., Like Drug Effect) relative to placebo. Subjective effects did not differ between oral CBD and placebo and were generally higher for CBD-dominant cannabis compared to vaporized CBD. CBD did not increase ratings for several items typically associated with acute cannabis/THC exposure (e.g., Paranoid). Women reported qualitatively higher ratings for Pleasant Drug Effect than men after vaporized CBD and CBD-dominant cannabis use. CBD-dominant cannabis increased heart rate compared to placebo. Cognitive/psychomotor impairment was not observed in any drug condition. CONCLUSIONS Vaporized CBD and CBD-dominant cannabis produced discriminable subjective drug effects, which were sometimes stronger in women, but did not produce cognitive/psychomotor impairment. Subjective effects of oral CBD did not differ from placebo. Future research should further elucidate the subjective effects of various types of CBD products (e.g., inhaled, oral, topical), which appear to be distinct from THC-dominant products.

中文翻译：

---

汽化和口服大麻二酚 (CBD) 以及以 CBD 为主的汽化大麻对不常吸食大麻的药效学影响。


简介 随着大麻/大麻合法化的扩大，以大麻二酚 (CBD) 作为主要成分的口服和吸入产品的使用和可用性有所增加。然而，很少有对照临床实验室研究评估口服或汽化 CBD 或以 CBD 为主的大麻的药效作用。方法 18 名健康成年人（9 名男性；9 名女性）完成了四次双盲、双模拟给药课程。疗程间隔≥1周，包括自行服用100毫克口服CBD、100毫克汽化CBD、汽化CBD主导大麻（100毫克CBD；3.7毫克THC）和安慰剂。研究结果包括：主观药物效应、生命体征、认知/精神运动表现以及全血 THC 和 CBD 浓度。结果 相对于安慰剂，汽化 CBD 和 CBD 主导的大麻提高了几个主观项目（例如药物效应）的评分。口服 CBD 和安慰剂之间的主观效果没有差异，并且与汽化 CBD 相比，以 CBD 为主的大麻的主观效果通常更高。 CBD 没有提高通常与急性大麻/ THC 暴露相关的几个项目的评级（例如偏执狂）。在使用汽化 CBD 和以 CBD 为主的大麻后，女性对令人愉悦的药物效果的评价比男性更高。与安慰剂相比，以 CBD 为主的大麻会增加心率。在任何药物状况下均未观察到认知/精神运动障碍。结论 汽化 CBD 和以 CBD 为主的大麻会产生可区分的主观药物效应，有时在女性中更强，但不会产生认知/精神运动障碍。口服 CBD 的主观效果与安慰剂没有差异。未来的研究应进一步阐明各类 CBD 产品的主观影响（例如、吸入、口服、外用），这似乎与以 THC 为主的产品不同。